HSBC Holdings
CERO

HSBC Holdings’s CERo Therapeutics CERO Stock Holding History

HSBC Holdings’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-365
Closed -$7.51M – 3100
2022
Q4 		$7.51M Hold
365
– – 0.01% 1078
2022
Q3 		$7.36M Buy
365
+234
+179% +$4.71M 0.01% 1021
2022
Q2 		$2.62M Buy
+131
New +$2.62M ﹤0.01% 1451

Other funds holding CERO

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

HSBC Holdings's CERO Position: Q1 2023 in Review

HSBC Holdings sold out of CERo Therapeutics (CERO) in Q1 2023, closing a stake of 365 shares — an estimated $7.51M sold.

HSBC Holdings first reported a position in CERO in Q2 2022 and held it in 3 quarters. The position peaked at $7.51M in Q4 2022. 15 funds tracked by Wall St. Rank hold CERO as of Q1 2023.

  • HSBC Holdings reported no remaining CERo Therapeutics position as of Q1 2023 after selling out during the quarter.
  • HSBC Holdings sold 365 CERo Therapeutics shares in Q1 2023, an estimated $7.51M.
  • HSBC Holdings first reported a position in CERo Therapeutics in Q2 2022 and held it in 3 quarters.
  • HSBC Holdings's CERo Therapeutics position peaked at $7.51M in Q4 2022.
  • 15 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2023.

Based on HSBC Holdings's 13F filing for Q1 2023, filed 15 May 2023.